- Home
- GAMB vs FHTX Comparison
GAMB vs FHTX Comparison
Compare GAMB & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GAMB | FHTX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 323.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GAMB | FHTX |
|---|---|---|
| Price | $2.39 | $4.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $8.36 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 1.1M | 127.9K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $6.06 | $8.89 |
| Revenue Next Year | $8.79 | $20.13 |
| P/E Ratio | $89.96 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $2.23 | $3.27 |
| 52 Week High | $12.74 | $6.95 |
Technical Indicators
Market Signals| Indicator | GAMB | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.02 | 47.09 |
| Support Level | $2.23 | $3.62 |
| Resistance Level | $5.67 | $5.82 |
| Average True Range (ATR) | 0.30 | 0.29 |
| MACD | -0.15 | 0.04 |
| Stochastic Oscillator | 4.89 | 65.14 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.